Prelude Therapeutics Incorporated (PRLD) 宣布,其针对PRT12396的研究性新药申请已获得美国食品药品监督管理局的许可。PRT12396是一种突变选择性JAK2V617F抑制剂,旨在靶向治疗相关的基因突变。
Prelude Therapeutics Incorporated (PRLD) 宣布,其针对PRT12396的研究性新药申请已获得美国食品药品监督管理局的许可。PRT12396是一种突变选择性JAK2V617F抑制剂,旨在靶向治疗相关的基因突变。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.